Title : rs622342 in SLC22A1, CYP2C9*2 and CYP2C9*3 and Glycemic Response in Individuals with Type 2 Diabetes Mellitus Receiving Metformin/Sulfonylurea Combination Therapy: 6-Month Follow-Up Study.

Pub. Date : 2020 Jun 20

PMID : 32575674






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 rs622342 in SLC22A1, CYP2C9*2 and CYP2C9*3 and Glycemic Response in Individuals with Type 2 Diabetes Mellitus Receiving Metformin/Sulfonylurea Combination Therapy: 6-Month Follow-Up Study. Sulfonylurea Compounds cytochrome P450 family 2 subfamily C member 9 Homo sapiens
2 CONCLUSION: The combination of metformin/sulfonylurea therapy led to the maximum glycemic control in individuals with T2DM carrying AA or AC genotypes in SLC22A1 and *1*3 in CYP2C9. Sulfonylurea Compounds cytochrome P450 family 2 subfamily C member 9 Homo sapiens